journal
https://read.qxmd.com/read/36759201/-161-tb-psma-radioligand-therapy-first-in-human-spect-ct-imaging
#1
JOURNAL ARTICLE
Akram Al-Ibraheem, Rahma M Doudeen, Diyaa Juaidi, Alaa Abufara, Stephan Maus
No abstract text is available yet for this article.
February 9, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36759200/psma-pet-ct-based-atlas-for-prostatic-bed-recurrence-after-radical-prostatectomy-clinical-implications-for-salvage-radiation-therapy-contouring-guidelines
#2
JOURNAL ARTICLE
Ida Sonni, Alan Dal Pra, Dylan P O'Connell, Zachary Ells, Matthias Benz, Kathleen Nguyen, Stephanie M Yoon, Jie Deng, Clayton Smith, Tristan Grogan, Nickolas G Nickols, Minsong Cao, Amar U Kishan, Jeremie Calais
Purpose: The aim of this study was to analyze the patterns of prostate bed (PB) recurrence in prostate cancer patients experiencing PSA persistence (BCP) or biochemical recurrence (BCR) after radical prostatectomy using 68 Ga-PSMA-11 PET/CT (PSMA PET) and evaluate the relationship between the RTOG clinical target volumes (CTVs) and PSMA PET-defined recurrence topography. Methods: Patients with BCP or BCR post radical prostatectomy and PB recurrence on PSMA PET were retrospectively included in the analysis. Two nuclear medicine physicians and 4 radiation oncologists manually delineated the PB recurrence and the CTV using the RTOG contouring guidelines on the PSMA PET/CT, respectively, blinded from each other...
February 9, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36759199/psma-gck01-a-generator-based-99m-tc-188-re-theranostic-ligand-for-the-prostate-specific-membrane-antigen
#3
JOURNAL ARTICLE
Jens Cardinale, Frederik L Giesel, Christina Wensky, Hendrik G Rathke, Uwe Haberkorn, Clemens Kratochwil
Introduction: Prostate-specific membrane antigen (PSMA)-theranostic has been introduced with Gallium-68 and Lutetium-177, the currently most used radionuclides. However, Rhenium-188 is a well-known generator based therapeutic nuclide completing a theranostic tandem with Technetium-99m and may offer an interesting alternative to the current state of the art. In the present work, we aimed towards the development of a PSMA-targeted 99m Tc-/188 Re-theranostic tandem. Methods: The ligand HYNIC-iPSMA was chosen as lead structure...
February 9, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36759198/the-emergence-of-somatostatin-antagonist-based-theranostics-paving-the-road-toward-another-success
#4
JOURNAL ARTICLE
Alessio Imperiale, Abhishek Jha, Leah Meuter, Guillaume P Nicolas, David Taïeb, Karel Pacak
No abstract text is available yet for this article.
February 9, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36759197/radioimmunoscintigraphy-and-pre-treatment-dosimetry-of-131-i-omburtamab-for-planning-treatment-of-leptomeningeal-disease
#5
JOURNAL ARTICLE
Neeta Pandit-Taskar, Milan Grkovski, Pat B Zanzonico, Keith S Pentlow, Shakeel Modak, Kim Kramer, John L Humm
Radiolabeled antibody treatment with 131 I-omburtamab, administered intraventricularly into the CSF space, can deliver therapeutic absorbed doses to sites of leptomeningeal disease. Assessment of distribution and radiation dosimetry is a key element in optimizing such treatments. Using a theranostic approach, we performed pre-treatment 131 I-omburtamab imaging and dosimetric analysis in patients prior to therapy. Methods: Whole-body planar images were acquired at 3±1 h, 23±2 h, and 47±2 h after intracranioventricular administration of 75±5 MBq of 131 I-omburtamab via an Ommaya reservoir...
February 9, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36732058/could-fap-targeted-molecular-imaging-replace-fdg-for-standard-of-care-oncologic-pet
#6
JOURNAL ARTICLE
Raghava Kashyap, Aravind S Ravi Kumar
No abstract text is available yet for this article.
February 2, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36732057/signaling-network-response-to-alpha-particle-targeted-therapy-with-actinium-225-labeled-minigastrin-analogue-225-ac-pp-f11n-reveals-radiosensitizing-potential-of-hdac-inhibitors
#7
JOURNAL ARTICLE
Yun Qin, Stefan Imobersteg, Stephan Frank, Alain Blanc, Tanja Chiorazzo, Philipp Berger, Roger Schibli, Martin P Béhé, Michal Grzmil
Alpha-particle emitters have recently been explored as valuable therapeutic radionuclides. Yet, toxicity to healthy organs and cancer radioresistance limit the efficacy of targeted alpha-particle therapy (TAT). Identification of the radiation-activated mechanisms, which drive cancer cell survival, provides opportunities to develop new points for therapeutic interference to improve efficacy and safety of TAT. Methods: Quantitative phosphoproteomics and matching proteomics followed by the bioinformatics analysis were employed to identify alterations in the signaling networks in response to TAT with actinium-225 labeled minigastrin analogue 225 Ac-PP-F11N in A431 cells, which overexpress cholecystokinin B receptor (CCKBR)...
February 2, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36732056/functional-imaging-of-chemo-brain-usefulness-of-nuclear-medicine-in-the-fog-coming-after-cancer
#8
JOURNAL ARTICLE
Agostino Chiaravalloti, Luca Filippi, Marco Pagani, Orazio Schillaci
The impact of chemotherapy on brain functionality has been widely investigated from a clinical perspective and there is a consensus on a significant impairment of multiple cognitive domains affecting cancer patients after treatment. Nuclear medicine offers a variety of biomarkers for the evaluation of possible effects of chemotherapy on the brain and for depicting brain changes after chemotherapy treatment. This review aims to summarize the most relevant findings on brain imaging in patients treated with chemotherapy for the most common oncological diseases...
February 2, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36732055/an-analysis-of-psma-pet-ct-positive-lymph-node-distribution-and-their-coverage-by-different-elective-nodal-radiation-volumes-in-postoperative-prostate-cancer-patients
#9
JOURNAL ARTICLE
Christian Trapp, Dmytro Oliinyk, Paul Rogowski, Rieke Von Bestenbostel, Ute Ganswindt, Minglun Li, Chukwuka Eze, Peter Bartenstein, Leonie Beyer, Harun Ilhan, Gabriel Sheikh, Lena Unterrainer, Christian Stief, Thilo Westhofen, Wolfgang G Kunz, Marcus Unterrainer, Claus Belka, Nina-Sophie Schmidt-Hegemann
Salvage elective nodal radiotherapy (sENRT) is a treatment option for biochemical persistent or recurrent patients with lymph node metastases (LN) after prostatectomy. Possible ENRT templates were proposed by the RTOG (2009), the PIVOTAL trialists (2015) and the NRG Oncology Group (2021). The goal of this study was to analyze the distribution of PSMA-PET/CT-positive LN and to compare the templates with regard to their LN coverage. Methods: We analyzed PSMA-PET/CT scans of 105 patients with PET-positive LN treated with sENRT from 2014 to 2019...
February 2, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36732054/efficacy-and-safety-of-124-i-mibg-dosimetry-guided-high-activity-131-i-mibg-therapy-of-advanced-pheochromocytoma-or-neuroblastoma
#10
JOURNAL ARTICLE
Ines Maric, Manuel Weber, Andre Prochnow, Jochen Schmitz, Nicole Unger, Benedikt M Schaarschmidt, Thorsten D Poeppel, Christoph Rischpler, Andreas Bockisch, Ken Herrmann, Walter Jentzen, Wolfgang P Fendler
Introduction: We aim to evaluate the efficacy and safety of 124 I-mIBG dosimetry guided high-activity 131 I-mIBG therapy of advanced pheochromocytoma or neuroblastoma. Methods: Fourteen patients with advanced pheochromocytoma or neuroblastoma, age 9 to 69 years, underwent 124 I-mIBG PET scans and whole-body retention measurements to assess the whole-body dose as a surrogate of bone marrow toxicity and tumor (absorbed) dose per unit of administered activity. Dosimetry results together with individual patient characteristics were combined to guide a single therapeutic activity to achieve a high tumor dose without exceeding toxicity threshold...
February 2, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36702555/radiolabeled-gpvi-fc-for-pet-imaging-of-multiple-extracellular-matrix-fibers-a-new-look-into-pulmonary-fibrosis-progression
#11
JOURNAL ARTICLE
Simon Isser, Andreas Maurer, Gerald Reischl, Martin Schaller, Irene Gonzalez-Menendez, Leticia Quintanilla-Martinez, Meinrad Gawaz, Bernd J Pichler, Nicolas Beziere
Invariably fatal and with a particularly fast progression, pulmonary fibrosis (PF) is currently devoid of curative treatment option. Routine clinical diagnosis relies on breathing tests and visualizing the changes in lung structure by computed tomography (CT), but anatomical information is often not sufficient to identify early signs of progressive PF. For more efficient diagnosis, additional imaging techniques were investigated in combination with CT, such as 18 F-Fluorodeoxyglucose (18 F-FDG) positron emission tomography (PET), although with limited success due to lack of disease specificity...
January 26, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36702554/incidental-detection-of-a-tenosynovial-giant-cell-tumour-of-the-thigh-on-68-ga-ga-fapi-pet-ct-presentation-of-an-unusual-case
#12
JOURNAL ARTICLE
Timur Sellmann, Felicitas Staak, Clemens Maurer, Gernot Rott, Oliver Witzke, Wolfgang Fendler, Hans-Ulrich Schildhaus, Lars Erik Podleska, Ken Herrmann, Christoph Rischpler
No abstract text is available yet for this article.
January 26, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36702553/clinical-implementation-of-177-lu-psma-617-in-the-united-states-lessons-learned-and-ongoing-challenges
#13
JOURNAL ARTICLE
Praful Ravi, Bridget Whelpley, Emma Kelly, Andrew Wolanski, Jolivette Ritzer, Matthew Robertson, Hina Shah, Alicia K Morgans, Xiao X Wei, Rajitha Sunkara, Mark Pomerantz, Mary-Ellen Taplin, Kerry L Kilbridge, Atish D Choudhury, Heather Jacene
No abstract text is available yet for this article.
January 26, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36657982/consecutive-psma-and-ar-pet-imaging-shows-positive-correlation-to-ar-and-psma-protein-expression-in-primary-hormone-na%C3%A3-ve-prostate-cancer
#14
JOURNAL ARTICLE
Valentin Al Jalali, Gabriel Wasinger, Sazan Rasul, Bernhard Grubmueller, Beatrix Wulkersdorfer, Theresa Balber, Markus Mitterhauser, Judit Simon, Marcus Hacker, Sharokh Shariat, Gerda Egger, Markus Zeitlinger
Rationale: The present study set out to investigate if PET imaging can be used as a potential substitute for immunohistochemical analysis of tumor samples in prostate cancer (PC) patients. Correlation between imaging signals of two PET tracers and the corresponding target structures was assessed. The first tracer was [68 Ga]Ga-PSMAHBED-CC([68 Ga]PSMA), which is already implemented in clinical routine. The second tracer was [18 F]-fluoro-5α-dihydrotestosterone([18 F]FDHT) which binds to the androgen receptor (AR)...
January 19, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36657981/molecular-imaging-of-pulmonary-inflammation-in-electronic-and-combustible-cigarette-users-a-pilot-study
#15
JOURNAL ARTICLE
Reagan R Wetherill, Robert K Doot, Anthony J Young, Hsiaoju Lee, Erin K Schubert, Corinde E Wiers, Frank T Leone, Robert H Mach, Henry R Kranzler, Jacob G Dubroff
Electronic cigarette (EC) use has increased dramatically, particularly among adolescents and young adults, which, like cigarette use, can cause pulmonary inflammation and increase the risk of lung disease. Methods: This preliminary study used positron emission tomography with 18 F-6-(1/2)(2-fluoro-propyl)-4-methylpyridin-2-amine (18 F-NOS) to quantify inducible nitric oxide synthase (iNOS) expression to characterize oxidative stress and inflammation in the lungs in vivo in three age- and sex-matched groups: (1) 5 EC users, (2) 5 cigarette smokers, and (3) 5 never smoke/vape controls...
January 19, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36657980/towards-single-time-point-image-based-dosimetry-of-177-lu-psma-617-therapy
#16
JOURNAL ARTICLE
Julia Brosch-Lenz, Astrid Delker, Friederike Völter, Lena M Unterrainer, Lena Kaiser, Peter Bartenstein, Sibylle Ziegler, Arman Rahmim, Carlos Uribe, Guido Böning
Radiopharmaceutical therapies (RPTs) with Lutetium-177 prostate-specific membrane antigen (PSMA) ligands have demonstrated promising results for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The lack of absorbed dose and effect relationships currently prevents from patient-specific activity personalization. To ease the implementation of dosimetry in routine clinic workflow of RPT, simplified methods such as single time point (STP) instead of multiple time point (MTP) imaging protocols are required...
January 19, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36657979/preliminary-clinical-experience-of-cholecystokinin-2-receptor-pet-ct-imaging-using-the-68-ga-labeled-minigastrin-analog-dota-mgs5-in-patients-with-medullary-thyroid-cancer
#17
JOURNAL ARTICLE
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J Virgolini
PET/CT imaging was performed in patients with advanced medullary thyroid cancer (MTC) with the new 68 Ga-labeled minigastrin analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (68 Ga-DOTA-MGS5) to evaluate the cholecystokinin-2 receptor expression status. Methods: Six patients with advanced MTC underwent PET/CT imaging with 68 Ga-DOTA-MGS5. From the images acquired one and two hours post injection (p.i.) preliminary data on the biodistribution and tumor targeting properties were evaluated in a retrospective analysis...
January 19, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36635088/developing-a-novel-patient-reported-outcomes-measure-for-prostate-cancer-patients-receiving-radionuclide-therapy
#18
JOURNAL ARTICLE
Lisa M Gudenkauf, Melody Chavez, Melinda L Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R Armstrong, Khaled Komrokji, Laura B Oswald, Heather S L Jim, Ghassan El-Haddad, Wolfgang Peter Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S Hofman, Adam P Dicker, Jeremie Calais, Scott T Tagawa, Brian D Gonzalez
The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly with recent FDA approval of the first Lutetium-177-PSMA-ligand. Current patient-reported outcomes (PRO) measures were designed to assess impacts of chemotherapy or surgery. We aimed to develop the first PRO measure for PC patients receiving RNT. Methods: First, we identified relevant symptoms/toxicities by reviewing published trials and interviews with PC patients receiving RNT ( n = 29), caregivers ( n = 14), and clinicians ( n = 11)...
January 12, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36635087/prostate-specific-membrane-antigen-expression-on-positron-emission-tomography-computed-tomography-in-patients-with-metastatic-castration-resistant-prostate-cancer-a-retrospective-observational-study
#19
JOURNAL ARTICLE
Letizia Calderoni, Elisa Maietti, Andrea Farolfi, Riccardo Mei, Karly S Louie, Michael Groaning, Stefano Fanti
Rationale: Monitoring therapy response in patients with metastatic castration-resistant prostate cancer ([m]CRPC) treated with novel hormonal therapies, taxanes and newly approved therapies is crucial for optimizing treatment. [68 Ga]Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography/computed tomography (PSMA PET/CT) is a promising target for managing treatment in patients with prostate cancer. PSMA is overexpressed in patients with mCRPC; understanding how expression might change in patients undergoing treatment could determine its potential for guiding clinical decisions...
January 12, 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/36604185/myocardial-external-efficiency-in-asymptomatic-severe-primary-mitral-regurgitation-using-11-c-acetate-positron-emission-tomography
#20
JOURNAL ARTICLE
Jens Sorensen, Johannes Bergsten, Tomasz Baron, Lovisa Holm Orndahl, Tanja Kero, Tomas Bjerner, Eva-Maria Hedin, Hendrik J Harms, Rafael Astudillo, Frank A Flachskampf
Subjects with asymptomatic moderate-severe or severe primary mitral regurgitation (MR) are closely observed for signs of progression or symptoms requiring surgical intervention. The role of myocardial metabolic function in progression of MR is poorly understood. We used 11 C-acetate positron emission tomography (PET) to non-invasively measure myocardial external efficiency (MEE), which is the energetic ratio of external cardiac work and left ventricular oxygen consumption. Methods and Results: 47 patients in surveillance with MR and no or minimal symptoms prospectively underwent PET, echocardiography and cardiac magnetic resonance imaging (CMR) on the same day...
January 5, 2023: Journal of Nuclear Medicine
journal
journal
20164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.